RNTX
Rein Therapeutics Inc
NASDAQ: RNTX · HEALTHCARE · BIOTECHNOLOGY
$1.36
+6.27% today
Updated 2026-04-30
Market cap
$40.66M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.96
Dividend yield
—
52W range
$1 – $2
Volume
0.1M
Rein Therapeutics Inc (RNTX) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
2 of 8
Last 8 quarters
Avg EPS surprise
-79.4%
Last 4 quarters
Revenue YoY growth
—
Most recent quarter
EPS YoY growth
+43.6%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
+12.6%
Last 3 reports
Positive reaction rate
67%
2 of 3 quarters
Largest single-day move
+30.6%
2026-04-06
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-04-06 | $-1.22 | — | $1.21 | $1.58 | +30.6% |
| 2025-12-31 | $-1.22 | -467.4% | $1.07 | $1.25 | +16.8% |
| 2025-11-14 | $-0.21 | -5.0% | $1.35 | $1.22 | -9.6% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2026-03-31 | — | $-1.22 | — | — | — |
| 2025-12-31 | $-0.22 | $-1.22 | -467.4% | — | — |
| 2025-09-30 | $-0.20 | $-0.21 | -5.0% | — | — |
| 2025-06-30 | $-0.21 | $-0.28 | -33.3% | — | — |
| 2025-03-31 | $-0.22 | $-2.16 | -881.8% | — | — |
| 2024-12-31 | $-0.48 | $-0.26 | +45.6% | — | — |
| 2024-09-30 | $-0.45 | $-0.27 | +40.0% | — | — |
| 2024-06-30 | $-0.42 | $-0.45 | -7.1% | — | — |
| 2024-03-31 | $-1.02 | $-0.86 | +15.7% | — | — |
| 2023-12-31 | $-0.16 | $-1.54 | -862.5% | — | — |
| 2023-09-30 | — | $-0.40 | — | — | — |
Frequently asked questions
Has Rein Therapeutics Inc beaten earnings estimates?
Rein Therapeutics Inc has beaten Wall Street EPS estimates in 2 of its last 8 quarterly reports, with an average EPS surprise of -79.4% over the last 3 quarters.
How does RNTX stock react to earnings?
RNTX stock has moved an average of +12.6% in the trading day following earnings over its last 3 reports, with positive reactions in 67% of those quarters.